SR ONE CAPITAL MANAGEMENT, LP - Q3 2022 holdings

$219 Million is the total value of SR ONE CAPITAL MANAGEMENT, LP's 4 reported holdings in Q3 2022. The portfolio turnover from Q2 2022 to Q3 2022 was 0.0% .

 Value Shares↓ Weighting
 ARCELLX INC.$103,235,000
+3.8%
5,500,0070.0%47.19%
-3.0%
DSGN  DESIGN THERAPEUTICS INC$94,075,000
+19.4%
5,626,4760.0%43.01%
+11.6%
NKTX  NKARTA INC.$17,547,000
+6.8%
1,333,3330.0%8.02%
-0.2%
 EFFECTOR THERAPEUTICS INC$3,889,000
-59.9%
6,822,1140.0%1.78%
-62.5%
Original filings

The following EDGAR filing(s) were analyzed to create this report:

  • View 13F-HR filed 2022-11-08
Signatures

The EDGAR filing(s) were signed by:

Top long-term holdings
NameQuarters ownedLatest quarter ownedMax weighting
DESIGN THERAPEUTICS INC8Q3 202368.1%
EFFECTOR THERAPEUTICS INC8Q3 202331.9%
ARCELLX INC.7Q3 202372.6%
NKARTA INC.6Q3 20238.0%
ARS PHARMACEUTICALS INC4Q3 202311.6%
MINERALYS THERAPEUTICS INC3Q3 202313.2%

View SR ONE CAPITAL MANAGEMENT, LP's complete holdings history.

Latest filings
TypeFiled
13F-HR2024-02-12
13F-HR2023-11-13
13F-HR2023-08-10
13F-HR/A2023-05-19
13F-HR2023-05-09
13F-HR2023-02-08
13F-HR2022-11-08
13F-HR2022-08-02
13F-HR2022-05-10
13F-HR2022-02-14

View SR ONE CAPITAL MANAGEMENT, LP's complete filings history.

Export SR ONE CAPITAL MANAGEMENT, LP's holdings